Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users

CMAJ. Canadian Medical Association Journal

Volumn 169, Issue 7, 2003, Pages 656-661

  Wood, Evan ^a,b,d   Montaner, Julio S G ^a,c   Yip, Benita ^a   Tyndall, Mark W ^a,b   Schechter, Martin T ^a,b   O'Shaughnessy, Michael V ^a,b   Hogg, Robert S ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; COVARIANCE; DISEASE COURSE; FEMALE; HEALTH CARE DELIVERY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PLASMA; REBOUND; REGRESSION ANALYSIS; RNA ANALYSIS; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0142120650     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337(11):725-33.
2. Montaner JS, Reiss P, Cooper D, Verra S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998;279(12):930-7.
3. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard GB, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society - USA Panel. JAMA 2000;283(3):381-90.
4. Karon JM, Fleming PL, Steketee RW, De Cock KM. HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001;91(7):1060-8.
5. Anderson KH, Mitchell JM. Differential access in the receipt of antiretroviral drugs for the treatment of AIDS and its implications for survival. Arch Intern Med 2000;160(20):3114-20.
6. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995;270(5240):1372-5.
7. Strathdee SA, Patrick DM, Currie SL, Cornelisse PG, Rekart ML, Montaner JS, et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 1997;11(8):F59-65.
8. Mellors JW, Munoz A, Giorgi JV, Margolick JB, Tassoni CJ, Bupta P, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126(12):946-54.
9. Palepu A, Yip B, Miller C, Strathdee SA, O'Shaughnessy MV, Montaner JS, et al. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 2001;15:423-4.
10. Wood E, Schechter MT, Tyndall MW, Montaner JS, O'Shaughnessy MV, Hogg RS. Antiretroviral medication use among injection drug users: two potential futures. AIDS 2000;14(9):1229-35.
11. Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001;286(20):2568-77.
12. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society - USA. JAMA 1996;276(2):146-54.
13. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA Panel. JAMA 1997;277(24):1962-9.
14. World Health Organization. Acquired immune deficiency syndrome (AIDS): interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidemiol Rec 1990;65:221-8.
15. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001;286(20):2560-7.
16. Cox DR. Regression models and life tables. J R Stat Soc Ser B 1972;34:187-202.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50(1):105-16.
18. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000;23(4):360-1.
19. Hogg RS, Heath KV, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, et al. Intermittent use of triple combination therapy is predictive of mortality at baseline and after one year of follow-up. AIDS 2002;16(7):1051-8.
20. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334(11):701-6.
21. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS 2003;17(5):711-20.
22. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001;15(9):1133-42.
23. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272(5265):1167-70.
24. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 1999;353(9156):863-8.
25. Lundgren JD, Mocroft A, Gatell JM, Ledergerber B, D'Aminio Monforte A, Hermans P, et al. A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002;185(2):178-87.
26. Mitty JA, Stone VE, Sands M, Macalino G, Flanigan T. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis 2002;34(7):984-90.
27. Sherer R, Stieglitz K, Narra J, Jasek J, Green L, Moore B, et al. HIV multidisciplinary teams work: support services improve access to and retention in HIV primary care. AIDS Care 2002;14(Suppl 1):S31-44.
28. Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA 1998;280(6):544-6.
29. Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, Crystal S, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res 2000;35(2):389-416.
30. Bamberger JD, Unick J, Klein P, Fraser M, Chesney M, Katz MH. Helping the urban poor stay with antiretroviral HIV drug therapy. Am J Public Health 2000;90(5):699-701.
31. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA 1998;280(6):547-9.
32. Antela A, Casado JL, Gonzalez MJ, Perez P, Perez-Elias MJ, Montilla P, et al. Influence of a methadone maintenance programme on the improved outcome of a cohort of injecting drug users with advanced HIV disease. AIDS 1997;11(11):1405-6.
33. Spittal PM, Craib KJ, Wood E, Laliberté N, Li K, Tyndall MW, et al. Risk factors for elevated HIV incidence rates among female injection drug users in Vancouver. CMAJ 2002;166(7):894-9.
34. Craib KJ, Spittal PM, Wood E, Laliberté N, Hogg RS, Li K, et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CAMJ 2003;168(1):19-24.
35. Palepu A, Tyndall MW, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J Acquir Immune Defic Syndr 2003;32(5):522-6.
36. Edlin BR, Irwin KL, Faruque S, McCoy CD, Word C, Serrano Y, et al. Intersecting epidemics - crack cocaine use and HIV infection among inner-city young adults. Multicenter Crack Cocaine and HIV Infection Study Team. N Engl J Med 1994;331(21):1422-7.
37. Rehm J, Gschwend P, Steffen T, Gutzwiller F, Dobler-Mikola A, Uchtenhagen A. Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet 2001;358(9291):1417-23